RLMD
Relmada Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.43
+1.37%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 28.6M | 744.6K | 46.2M | 54.8M | 113.3M |
| SG&A Expense | 36.5M | 311.9K | 37.7M | 48.9M | 47.9M |
| General & Admin Expense | 36.5M | 311.9K | 37.7M | 48.9M | 47.9M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | 58.0M | — | — | 923.00 |
| Total Operating Expenses | 65.1M | 59.1M | 83.9M | 103.7M | 161.2M |
| Cost and Expenses | 65.1M | 59.1M | 83.9M | 103.7M | 161.2M |
| Operating Income (EBIT) | (65.1M) | (59.1M) | (83.9M) | (103.7M) | (161.2M) |
| Non-Operating | |||||
| Interest Income | 3.9M | 1.4M | 3.5M | 5.2M | 2.7M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 3.9M | 1.4M | 3.5M | 5.2M | 2.7M |
| Other Non-Op Income/Expense | 3.2M | 1.7M | 3.9M | 4.9M | 4.2M |
| Non-Operating Income (excl Interest) | (3.2M) | (1.7M) | (3.9M) | (4.9M) | (4.2M) |
| EBT (Pre-Tax Income) | (61.9M) | (57.4M) | (80.0M) | (98.8M) | (157.0M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (61.9M) | (57.4M) | (80.0M) | (98.8M) | (157.0M) |
| Earnings from Cont. Ops | (61.9M) | (57.4M) | (80.0M) | (98.8M) | (157.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (61.9M) | (57.4M) | (80.0M) | (98.8M) | (157.0M) |
| Per Share | |||||
| Basic EPS | ($0.92) | ($1.45) | ($2.65) | ($3.28) | ($5.30) |
| Diluted EPS | ($0.92) | ($1.45) | ($2.65) | ($3.28) | ($5.30) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 112.4M | 39.5M | 30.2M | 30.1M | 29.6M |
| Diluted Shares Outstanding | 112.4M | 39.5M | 30.2M | 30.1M | 29.6M |
| Profitability Metrics | |||||
| EBITDA | (61.9M) | (57.4M) | (80.0M) | 4.9M | (157.0M) |
| D&A | — | — | — | 103.7M | 2.0K |
| EBIT | (61.9M) | (57.4M) | (80.0M) | (98.8M) | (157.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026